Aspirin for Postpartum Patients With Preeclampsia

Part of paid clinical trials in Long Beach, California.

Sponsor
MemorialCare Health System
Study ID
NCT05924971
Phase
PHASE2
Status
Recruiting

Conditions

  • Preeclampsia Postpartum

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Aspirin 81Mg Ec Tab — DRUG
    Aspirin 81 mg 1 tablet by mouth. Participants randomized to receive aspirin in addition to standard blood pressure management will receive the study medication nightly at 20:00, with first dose initiated within 24 hours of delivery.

Study Details

The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

Key Dates

Start date
Jul 26, 2023
Status verified
May 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
86 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Standard blood pressure control plus aspirin 81 mg
    Standardized postpartum blood pressure control Aspirin 81 mg by mouth x 1 week post-delivery
  • No Intervention: Standard blood pressure control
    Standardized postpartum blood pressure control

Primary Outcome Measure

Reduction in sFlt-1 [ Time Frame: 1 week postpartum ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Miller Children's and Women's Hospital, Long Beach/MemorialCare Long BeachLong BeachCalifornia90740
Megan Oakes, MD
562-997-8510

Find similar trials in Long Beach, CA

Related Studies